公开(公告)号：US09492404B2

公开(公告)日：2016-11-15

申请号：US13209201

申请日：2011-08-12

Applicant: Richard L. Watson ,  Anthony B. Wood ,  Gregory J. Archambeau

Inventor： Richard L. Watson ,  Anthony B. Wood ,  Gregory J. Archambeau

IPC: A61K38/21 ,  A61P25/28 ,  A61K9/00 ,  A61K31/46 ,  A61K31/47 ,  A61K31/137 ,  A61P29/00 ,  A61K31/58 ,  A61K31/56 ,  A61K31/167 ,  A61K31/44 ,  A61K31/436 ,  A61K31/136 ,  A61P25/00 ,  A61K39/395 ,  A61K38/13 ,  A61K41/00

CPC classification number: A61K31/136 ,  A61K31/137 ,  A61K31/167 ,  A61K31/436 ,  A61K31/44 ,  A61K31/46 ,  A61K31/47 ,  A61K31/56 ,  A61K31/58 ,  A61K38/13 ,  A61K38/21 ,  A61K41/0004 ,  A61K2300/00

Abstract: Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.

Abstract translation: 提供了包含电荷稳定的含氧纳米结构的离子水溶液的电动改变的流体（例如，电动改变的富含气体的流体和溶液），其量足以治疗炎症性神经变性病症或疾病（例如，甲状腺炎） 或其至少一种症状。 电动改变的流体或治疗组合物和方法包括任选与其它治疗剂组合的电动改变的离子水性流体。 特定方面提供了调节tau蛋白的磷酸化。 特定方面提供通过调节细胞膜电位和/或电导中的至少一种来调节或调节与所述炎症反应相关的细胞内信号转导，膜蛋白例如膜受体，包括但不限于G-蛋白偶联受体（GPCR） ，和细胞间结（例如，紧密连接处，间隙连接处，zona adherins和desmasomes）。 其它实施方案包括用于电动改变的流体和治疗组合物的特定给药途径或制剂。

公开(公告)号：US20160303187A1

公开(公告)日：2016-10-20

申请号：US15101118

申请日：2014-12-03

Applicant: ASTUTE MEDICAL, INC. ,  UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Paul McPherson ,  John A. Kellum

IPC: A61K38/13 ,  G01N33/68 ,  A61K45/06

CPC classification number: A61K38/13 ,  A61K31/357 ,  A61K31/366 ,  A61K31/436 ,  A61K31/437 ,  A61K31/453 ,  A61K31/55 ,  A61K31/585 ,  A61K38/1754 ,  A61K38/55 ,  A61K45/06 ,  G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50

Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells

Abstract translation: 本发明的目的是提供用于通过用调节细胞周期的化合物治疗受试者来保护受试者免受急性肾损伤的方法和组合物。 调节细胞周期可以包括诱导G0 / G1细胞周期停滞和/或诱导细胞周期进程。 如下所示，即使单次施用诱导G0 / G1细胞周期停滞的化合物也可以保护受试者免受AKI的侵害，并且可以在已知有害的各种治疗或病症之前或作为治疗之后预防使用 到肾脏，随后释放逮捕。 一旦AKI建立，可以诱导细胞周期进程以增加丢失和损伤的细胞的替换

公开(公告)号：US09463114B2

公开(公告)日：2016-10-11

申请号：US14472844

申请日：2014-08-29

Applicant: MATI THERAPEUTICS INC.

Inventor： Steven A. Odrich ,  Liane C. Glazer

IPC: A61F9/00 ,  A61F9/007 ,  A61K9/00

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61F9/007 ,  A61F9/00772 ,  A61K31/5575 ,  A61K38/13

Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Abstract translation: 用于向受试者施用诸如药物的活性剂的方法和装置使用已经施用活性剂的眼部植入物例如泪点塞。 将植入物安装在受试者的眼睛处，以通过眼睛的组织施用活性剂。

公开(公告)号：US20160271207A1

公开(公告)日：2016-09-22

申请号：US15171866

申请日：2016-06-02

Applicant: Allergan, Inc.

Inventor： Wendy M. Blanda ,  Hongwen Ma Rivers ,  David A. Marsh ,  Michelle Luu

IPC: A61K38/13 ,  A61K47/38 ,  A61K47/32

CPC classification number: A61K38/13 ,  A61K9/0048 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  C07K1/306 ,  C07K7/645

Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.

公开(公告)号：US20160271058A1

公开(公告)日：2016-09-22

申请号：US14659323

申请日：2015-03-16

Applicant: GAVIS PHARMACEUTICALS

Inventor： Aman Trehan ,  Bala Chandran Nayar

IPC: A61K9/107 ,  A61K47/44 ,  A61K38/13

CPC classification number: A61K9/107 ,  A61K9/0048 ,  A61K38/13 ,  A61K47/18 ,  A61K47/20 ,  A61K47/44

Abstract: The invention relates to an ophthalmic emulsion composition of cyclosporine in the form of oil-in-water emulsion. The emulsion remains stable at 25° C. for at least 6 months or at 45° C. for at least 45 days. The composition is useful for treating a dry eye condition or glaucoma, and preferably for increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

Abstract translation: 本发明涉及水包油乳液形式的环孢菌素的眼用乳液组合物。 乳液在25℃保持至少6个月或在45℃保持至少45天。 该组合物可用于治疗干眼症状或青光眼，并且优选用于增加由于与角膜结膜炎西雅卡相关的眼部炎症而推定其泪液产生被抑制的患者的泪液生成。

公开(公告)号：US20160243037A1

公开(公告)日：2016-08-25

申请号：US15029652

申请日：2014-10-15

Applicant: Rebecca BADER

Inventor： Rebecca Bader

IPC: A61K9/107 ,  A61K47/34 ,  A61K31/728 ,  A61K38/13 ,  A61K31/366 ,  A61K31/573 ,  A61K47/36

CPC classification number: A61K9/1075 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/366 ,  A61K31/573 ,  A61K31/726 ,  A61K31/728 ,  A61K38/13 ,  A61K47/34 ,  A61K47/36 ,  A61K2300/00

Abstract: PSA-PCL micelles were developed as carrier systems for pharmaceutical drugs. As an example, cyclosporine A (CyA) was encapsulated in the micelles and physical characterization, including size and zeta potential, demonstrated that the micelles possess favorable properties for drug delivery. In vitro studies verified that rheumatoid arthritis synovial fibroblasts are able to internalize the CyA-loaded micelles. CyA was released from the PSA-PCL micelle upon uptake and subsequently, partitioned into the phospholipid membrane. The PSA-PCL micelles also demonstrated improved therapeutic efficacy in drug delivery when used to deliver statins and disease modifying anti-rheumatic drugs (DMARDs).

Abstract translation: PSA-PCL胶束被开发为药物的载体体系。 作为一个例子，环孢菌素A（CyA）被包封在胶束中并且物理表征，包括大小和ζ电位，证明了胶束具有药物递送的有利性质。 体外研究证实，类风湿关节炎滑膜成纤维细胞能够内化载有CyA的胶束。 CyA在摄取后从PSA-PCL胶束中释放，随后分配成磷脂膜。 当PSA-PCL胶束用于递送他汀类药物和疾病改变抗风湿药物（DMARDs）时，PSA-PCL胶束也显示出改善药物递送的治疗效果。

公开(公告)号：US20160228491A1

公开(公告)日：2016-08-11

申请号：US15016782

申请日：2016-02-05

Applicant: Stealth BioTherapeutics Corp

Inventor： D. Travis Wilson

IPC: A61K38/07 ,  C07K5/11 ,  C07K5/107 ,  A61K31/5415 ,  A61K45/06

CPC classification number: C07K5/1019 ,  A61K31/4152 ,  A61K31/5415 ,  A61K38/00 ,  A61K38/13 ,  A61K45/06 ,  C07K5/06078 ,  C07K5/06086 ,  C07K5/06095 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0817 ,  C07K5/1008 ,  C07K5/1016 ,  C07K5/1024 ,  A61K2300/00

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2′6′-Dmt-Lys-Phe-NH2.

Abstract translation: 本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括单独给予吩嗪-3-酮和/或吩噻嗪-3-酮衍生物，类似物或其药学上可接受的盐，或与其中一种或 更多的活性剂（例如芳族阳离子肽）。 本技术提供了与吩嗪-3-酮或吩噻嗪-3-酮衍生物连接的芳香族阳离子肽及其用途相关的组合物。 在一些实施方案中，芳族 - 阳离子肽包含D-Arg-2'6'-Dmt-Lys-Phe-NH2。

公开(公告)号：US20160228345A1

公开(公告)日：2016-08-11

申请号：US14852374

申请日：2015-09-11

Applicant: Allergan, Inc.

Inventor： Steven G. Yoelin

IPC: A61K8/64 ,  A61K8/34 ,  A61K8/31 ,  A61K8/39 ,  A61K8/02 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q7/00 ,  A61K8/06 ,  A61K8/42 ,  A61K8/04

CPC classification number: A61K8/64 ,  A61K8/0208 ,  A61K8/042 ,  A61K8/046 ,  A61K8/06 ,  A61K8/31 ,  A61K8/34 ,  A61K8/345 ,  A61K8/39 ,  A61K8/42 ,  A61K9/0014 ,  A61K31/5575 ,  A61K38/13 ,  A61K2800/596 ,  A61K2800/70 ,  A61K2800/874 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q7/00 ,  A61K2300/00

Abstract: The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited toalopecia areata. The present invention is also directed to compositions containing bimatoprost and cyclosporine A to grow hair on the scalp and other areas of the body and methods of administration of the compositions.

公开(公告)号：US09410123B2

公开(公告)日：2016-08-09

申请号：US12991096

申请日：2009-05-06

Applicant: Robert Lanza ,  Shi-Jiang Lu

Inventor： Robert Lanza ,  Shi-Jiang Lu

IPC: C12N5/00 ,  C12N5/0789

CPC classification number: C12N5/0647 ,  A61K35/12 ,  A61K35/28 ,  A61K35/44 ,  A61K38/13 ,  A61K45/06 ,  A61K2035/124 ,  A61N5/10 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/26 ,  C12N2506/02 ,  C12N2506/45

Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.

Abstract translation: 公开了在体外产生和扩大人血管瘤集落形成细胞和非移植血管瘤细胞的方法以及扩增和使用这些细胞的方法。 该方法允许生产大量的血管瘤集落形成细胞，非移植血管瘤细胞以及衍生细胞，如造血细胞和内皮细胞。 通过所公开的方法获得的细胞可用于各种研究，临床和治疗应用。 人类非移植血管瘤细胞是与成血管细胞和人类血管瘤集落形成细胞相关但不同的新型祖细胞群。 本发明还提供包含血管瘤集落形成细胞，非移植血管瘤细胞或与其分化的细胞的组合物，制剂和溶液。 组合物，制剂和溶液包括冷冻保存的制剂和基本纯化的制剂，以及与可以移入骨髓的相关成血管细胞祖细胞类型组合配制的混合组合物。

公开(公告)号：US20160213611A1

公开(公告)日：2016-07-28

申请号：US15090377

申请日：2016-04-04

Applicant: Sigmoid Pharma Limited

Inventor： Ivan Coulter ,  Vincenzo Aversa

IPC: A61K9/00 ,  A61K31/502 ,  A61K38/13 ,  A61K9/48 ,  A61K31/58 ,  A61K9/16

CPC classification number: A61K9/0053 ,  A61K9/16 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/1694 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5036 ,  A61K9/5042 ,  A61K31/223 ,  A61K31/502 ,  A61K31/56 ,  A61K31/58 ,  A61K38/13 ,  A61K2300/00

Abstract: A method for treating intestinal fibrosis in a subject, comprising enterally administering a steroid to the subject. The steroid may be in a multiple minibead formulation.

Abstract translation: 一种用于治疗受试者的肠纤维化的方法，包括向所述受试者肠内施用类固醇。 类固醇可以是多重微型制剂。